NCT07416188 2026-04-17
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Not yet recruiting
Clinical Trials
136 trialsNCT05588141 2026-04-16
A Phase I/II Study of Zotiraciclib for Recurrent Malignant Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05099003 2026-04-14
A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG)
National Cancer Institute (NCI)
Phase 1/2 Recruiting
NCT06607692 2026-04-14
LUPARPED
Fundación de investigación HM
Phase 1/2 Recruiting
NCT05278208 2026-04-13
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Phase 1/2 Recruiting
NCT06810544 2026-04-13
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Tango Therapeutics, Inc.
Phase 1/2 Recruiting
NCT07468136 2026-04-13
Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas
Mayo Clinic
Phase 1/2 Not yet recruiting
NCT06329570 2026-04-09
Safety and Efficacy of Bevacizumab in Combination With NaviFUS System for the Treatment of Recurrent Glioblastoma Multiforme (rGBM)
NaviFUS Corporation
Phase 1/2 Recruiting
NCT05094336 2026-03-31
MTAPESTRY 101
Amgen
Phase 1/2 Active not recruiting
NCT02650401 2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2 Active not recruiting
NCT06763965 2026-03-23
Evaluating the Safety and Efficacy of BioTTT001 in Patients With Recurrent/Progressive High-grade Glioma.
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
NCT07126990 2026-03-23
Clinical Study of a Novel Oncolytic Virus Ad-TD-nsIL12 in the Treatment of Primary High-grade Glioma
Beijing Bio-Targeting Therapeutics Technology Co., Ltd
Phase 1/2 Enrolling by invitation
NCT06161519 2026-03-19
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications
National Institutes of Health Clinical Center (CC)
Phase 1/2 Recruiting
NCT05417594 2026-03-12
CERTIS1
AstraZeneca
Phase 1/2 Recruiting
NCT06504381 2026-03-11
DB107-RRV, DB107-FC, and Radiation Therapy With or Without Temozolomide (TMZ) for High Grade Glioma
University of California, San Francisco
Phase 1/2 Recruiting
NCT05660408 2026-03-09
RNA PRIME
University of Florida
Phase 1/2 Active not recruiting
NCT04238819 2026-03-02
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
Eli Lilly and Company
Phase 1/2 Completed
NCT03510208 2026-02-09
Panitumumab-IRDye800 in Diagnosing Participants With Malignant Glioma Undergoing Surgery
Stanford University
Phase 1/2 Recruiting
NCT07389278 2026-02-05
Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)
University of California, San Francisco
Phase 1/2 Not yet recruiting
NCT04201457 2026-02-03
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
Pediatric Brain Tumor Consortium
Phase 1/2 Active not recruiting
NCT04773782 2026-01-13
A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Blueprint Medicines Corporation
Phase 1/2 Completed
NCT03212742 2025-12-04
OLA-TMZ-RTE-01
Centre Francois Baclesse
Phase 1/2 Active not recruiting
NCT03687957 2025-11-25
rhIL-7-hyFc on Increasing Lymphocyte Counts in Patients With Newly Diagnosed Non-severe Lymphopenic Gliomas Following Radiation and Temozolomide
Washington University School of Medicine
Phase 1/2 Active not recruiting
NCT07243470 2025-11-24
TARLATEM
Centre Leon Berard
Phase 1/2 Recruiting
NCT07243340 2025-11-21
A Phase I/IIa Study of C5252 in Patients With Intracranial Tumor
ImmVira Pharma Co. Ltd
Phase 1/2 Not yet recruiting
NCT04299191 2025-11-20
Study of LAM561 Acid in Pediatric Patients With Malignant Glioma and Other Advanced Solid Tumors
Laminar Pharmaceuticals
Phase 1/2 Recruiting
NCT04094610 2025-11-19
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
Turning Point Therapeutics, Inc.
Phase 1/2 Recruiting
NCT06011109 2025-10-02
Treatment of Patients With Recurrent High-Grade Glioma With APG-157 and Bevacizumab
Aveta Biomics, Inc.
Phase 1/2 Recruiting
NCT05736406 2025-09-11
A Dose-escalation Clinical Study of Intraoperative Photodynamic Therapy of Glioblastoma
Hemerion Therapeutics
Phase 1/2 Recruiting
NCT04977375 2025-09-03
Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma
Cedars-Sinai Medical Center
Phase 1/2 Recruiting
NCT01478178 2025-08-29
Safety Study of VAL-083 in Patients With Recurrent Malignant Glioma
Kintara Therapeutics, Inc.
Phase 1/2 Completed
NCT03330197 2025-08-12
A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG
Alaunos Therapeutics
Phase 1/2 Terminated
NCT02655601 2025-06-08
BMX-HGG
BioMimetix JV, LLC
Phase 1/2 Completed
NCT02311582 2025-05-29
MK-3475 in Combination With MRI-guided Laser Ablation in Recurrent Malignant Gliomas
Washington University School of Medicine
Phase 1/2 Completed
NCT06712875 2025-05-29
MAPK Inhibition Combined With Anti-PD1 Therapy for BRAF-altered Pediatric Gliomas
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Recruiting
NCT05664243 2025-05-01
A Phase 1b / 2 Drug Resistant Immunotherapy With Activated, Gene Modified Allogeneic or Autologous γδ T Cells (DeltEx) in Combination With Maintenance Temozolomide in Subjects With Recurrent or Newly Diagnosed Glioblastoma
In8bio Inc.
Phase 1/2 Active not recruiting
NCT03690869 2025-04-08
REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma
Regeneron Pharmaceuticals
Phase 1/2 Terminated
NCT01906385 2025-03-26
Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT)
Plus Therapeutics
Phase 1/2 Recruiting
NCT05737212 2025-02-21
Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas
Dawonmedax Co., Ltd.
Phase 1/2 Terminated
NCT02960230 2025-01-22
H3.3K27M Peptide Vaccine With Nivolumab for Children With Newly Diagnosed DIPG and Other Gliomas
University of California, San Francisco
Phase 1/2 Completed
NCT06703255 2025-01-15
A Phase 2 Study of HX301 in Patients with High-grade Giloma
Hangzhou Hanx Biopharmaceuticals, Ltd.
Phase 1/2 Recruiting
NCT05500508 2024-12-24
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Aminex Therapeutics, Inc.
Phase 1/2 Terminated
NCT04267146 2024-12-02
NIVOGLIO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Completed
NCT06640582 2024-11-05
BAH2472
Essen Biotech
Phase 1/2 Recruiting
NCT03234595 2024-09-19
A Phase I/IIa Study of Cerebraca Wafer Plus Adjuvant Temozolomide (TMZ) in Patients With Recurrent High Grade Glioma
Everfront Biotech Co., Ltd.
Phase 1/2 Completed
NCT03879512 2024-09-19
Autologous Dendritic Cells, Metronomic Cyclophosphamide and Checkpoint Blockade in Children With Relapsed HGG
Wuerzburg University Hospital
Phase 1/2 Completed
NCT06258018 2024-08-30
ONC-2022-001
Istituto Clinico Humanitas
Phase 1/2 Not yet recruiting
NCT06562621 2024-08-20
Clinical Study on the Safety and Efficacy of Novel Oncolytic Virus in the Treatment of Recurrent Malignant Glioma
Beijing Neurosurgical Institute
Phase 1/2 Completed
NCT04497142 2024-08-05
Effect of Perampanel on Peritumoral Hyperexcitability in HGG
Dana-Farber Cancer Institute
Phase 1/2 Completed
NCT01837862 2024-07-05
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Northwell Health
Phase 1/2 Completed